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 Introduction 
 Healthy individuals participate in clinical trials 1 and before trial 
enrolment they undergo rigorous screening procedures for medical 
abnormalities that may render them ineligible. 1,2 Screening can 
identify previously unrecognized medical conditions with clear 
ethical implications. 3 Conversely, obtaining information about 
personal health status can actually be a motivation for volunteer 
participation in such studies. 1 
 Th erefore estimates of the probability of incidental fi ndings 
in healthy subjects are highly relevant to the informed consent of 
potential participants. 1–3 In addition, although these apparently 
healthy volunteers may not be entirely representative of the 
general population, data on incidental fi ndings identifi ed at 
screening provide a useful snapshot of morbidity in healthy 
individuals in the community setting who may infrequently 
access health services. 
 Despite the importance of incidental diagnosis at clinical trial 
screening, the frequency and nature of these fi ndings have been 
largely unexplored in healthy subjects, and few data are available 
to guide those conducting healthy volunteer clinical trials. Here 
we describe the frequency and characteristics of incidental medical 
diagnoses in a large cohort of healthy clinical trial volunteers. 
 Methods 
 Participants and study design 
 Case report fi les (CRFs) of all healthy volunteers aged between 
18 and 65 who were screened for participation in phase I/IIa 
candidate vaccine trials at the Centre for Clinical Vaccinology 
and Tropical Medicine, University of Oxford, between July 1999 
and June 2010 were reviewed. 
 Details of screening procedures undertaken have been 
described in detail, 4 and remained consistent throughout the study 
period. In brief, all participants underwent comprehensive clinical 
evaluation by a study investigator. Hematological, biochemical, and 
blood-borne virus testing was performed by the local diagnostic 
laboratory according to validated protocols. Family practitioners 
were contacted (with participant consent) to corroborate medical 
history and previous testing. Th e lead investigator in each trial 
was responsible for determining the clinical signifi cance of any 
laboratory abnormalities with reference to the relevant clinical 
trial protocol and standardized laboratory reference ranges, 
which remained consistent throughout the study period. Th e 
lead investigator identifi ed clinical diagnoses in consultation 
with the principal trial investigator ± the local safety monitor. All 
volunteers excluded on medical grounds were referred to their 
family practitioner or an appropriate specialist. 
 Demographic and clinical data were extracted from CRFs and 
entered into an electronic database (Microsoft  Excel, Microsoft , 
Redmond, WA, USA), and 10% of entries were crosschecked with 
source documents to ensure accurate transcription. We excluded 
from the analysis volunteers with out of range laboratory fi ndings 
for which the clinical signifi cance could not be determined, and 
volunteers with preexisting medical diagnoses that had been 
established before screening procedures were undertaken (i.e., 
reported by the volunteer or identifi ed in a report from the family 
practitioner). 
 Ethics 
 All trials were conducted according to the principles of Good 
Medical Practice and the Declaration of Helsinki. Th e Oxfordshire 
Research Ethics Committee (OxREC) and/or the UK Department 
of Health Gene Th erapy Advisory Committee (GTAC) provided 
ethical committee approval for all studies. All participants 
provided written informed consent before any study procedure 
being carried out. 
 Statistical analysis 
 Due to the broad range and low frequency of individual 
abnormalities, descriptive methods were used to analyze clinical 
data on newly identifi ed medical abnormalities, and statistical 
 Incidental Diagnosis in Healthy Clinical Trial Subjects 
 Christopher J.A.  Duncan, B.Med.Sci, M.B.Ch.B, D.T.M.H., M.R.C.P.  1 ,2 ,  Rosalind  Rowland, B.Sc., B.M.  1  ,  Patrick J.  Lillie, M.B.Ch.B., D.T.M.H., 
M.R.C.P.  1  ,  Joel  Meyer, B.M.B.Ch., M.A., M.C.R.P.  1  ,  Susanne H.  Sheehy, B.M.B.Ch., D.T.M.H., M.R.C.P.  1  ,  Geraldine A.  O’Hara, M.B.Ch.B., M.R.C.P.  1  , 
 Matthew  Hamill, M.Sc., M.R.C.P.  1  ,  Hannah  Donaldson  1  ,  Laura  Dinsmore, B.A.  1  ,  Ian D.  Poulton, Dip.H.E. (Adult Nursing)  1  ,  Sarah C.  Gilbert, 
B.Sc., Ph.D.  1  ,  Helen  McShane, M.B.B.S., B.Sc., Ph.D., F.R.C.P.  1  , and  Adrian V.S.  Hill, D.M., D.Phil.  1  
 Brief Report 
DOI: 10.1111/j.1752-8062.2011.00393.x
 1 Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Drive, OX3 7LJ, United Kingdom;  2 Sir William Dunn School of Pathology, University of Oxford, 
South Parks Road, OX1 3RE, United Kingdom .
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.
 Correspondence: Christopher J.A. Duncan ( chrisduncan@doctors.net.uk ) 
 Abstract
 Previously unrecognized medical conditions identifi ed in volunteers for early phase clinical studies have signifi cant clinical and ethi-
cal implications for the participant. It is therefore crucial that the potential for unexpected diagnosis is addressed during the informed 
consent process. But the frequency of incidental diagnosis in healthy volunteers who attend for clinical trial screening remains unclear. 
To assess this we retrospectively analyzed 1,131 independent screening visits for 990 volunteers at a single academic center over a 
10-year period to describe the frequency and nature of new clinical fi ndings. Overall 23 of 990 volunteers (2.3%) were excluded at 
screening for a newly diagnosed medical abnormality. Some clinically important conditions, such as nephrotic syndrome and familial 
hypercholesterolemia were identifi ed. The frequency of abnormalities was associated with increasing age in males ( p = 0.02  2 for 
trend) but not females ( p = 0.82). These data will assist those planning and conducting phase I/II vaccine trials in healthy volunteers, 
and importantly should strengthen the informed consent of future trial participants. Clin Trans Sci 2012; Volume 5: 348–350
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analysis was restricted to investigating associations between 
abnormalities as a whole and demographic factors (age and 
gender) and screening period, using the chi-square and chi-square 
 test for trend for categorical variables, and the Mann-Whitney test 
for continuous variables. Statistical analysis was performed using 
GraphPad Prism (GraphPad Soft ware, Version 5.0, San Diego, 
CA, USA), and a two-tailed alpha value of <0.05 was considered 
signifi cant. 
 Results and Discussion 
 We analyzed 1,131 screening attendances for 990 healthy 
volunteers aged 18–65 (504 males, 483 females, 3 gender not 
specifi ed), identifying previously unrecognized fi ndings in 23 
(2.3%) individuals (14 males, 9 females,  p = 0.12,  2 ). Th ese are 
described in  Table 1 . We excluded from the analysis 25 of 990 
(2.5%) individuals with out of range laboratory abnormalities 
for which clinical signifi cance could not be determined from the 
database or from CRFs, and excluded 13 of 990 (1.3%) volunteers 
with previously diagnosed medical conditions. 
 We identifi ed several clinically important diagnoses, such as 
nephrotic syndrome, familial hypercholesterolemia, and chronic 
viral hepatitis ( Table 1 ), reinforcing the accepted importance of 
volunteer screening before enrolment. 1,2 Overall around one in 
45 apparently healthy volunteers had an unexpected fi nding. Th is 
value is likely an underestimate of the true frequency that would 
be expected in a normal distribution of individuals 
aged 18–65, because younger volunteers were 
over represented in this cohort: Even within the 
oldest age group (range 41–65), the median ages 
of male and female volunteers were 46.6 years 
(interquartile range, IQR: 42.9–49.2) and 46.3 
years (IQR: 43.3–50.2), respectively. Frequency of 
diagnosis in males increased with age ( p = 0.02  2 
for trend), although this trend was not observed 
in females ( p = 0.82). However, the trend in male 
volunteers was not confounded by an increase in 
the ages of the male volunteers excluded within the 
oldest age group (median 42.2 [IQR: 40.2–46.4], 
p = 0.08 Mann–Whitney test). Intriguingly, a 
greater proportion of conditions were identifi ed 
from 2009 compared to 1999–2008 ( p = 0.01,  2 ). 
Although clinical protocols were unchanged during 
this period, the increase in unexpected fi ndings was 
temporally associated with an increase in volunteer 
recruitment, 5 possibly suggesting a change in the 
source of volunteers recruited, or alternatively an 
increase in the baseline morbidity of volunteers 
screened during this period. 
 As we have noted, the characteristics of this 
cohort might not reflect those of the general 
adult population, and may not be generalizable 
to healthy volunteer populations in other settings. 
Information on potential confounding factors such 
as ethnicity or socioeconomic status, and on the 
long-term outcome of the conditions identifi ed was 
unavailable for this analysis. However, these data 
represent a large cohort of individuals screened at a 
single academic center using uniform procedures, 
and are consistent with a pharmaceutical industry 
healthy volunteer study, 6 and with similar data 
from over 20 years ago. 2 More recent studies have 
focused on African settings with greater baseline morbidity, 7 or 
on incidental fi ndings during neuroimaging studies of healthy 
subjects, 8 but incidental clinical diagnosis in healthy subjects 
remains a largely unexplored area. 
 Th e informed consent process for healthy subjects recruited to 
clinical trials should always involve an indication of the probability 
of incidental diagnosis, together with a clear statement of the 
actions to be taken in response to any problems identifi ed, 9,10 not 
least because information on incidental diagnosis may provide a 
valuable opportunity for clinical intervention. 
 Confl icts of Interests 
 SCG, GAO, HM and AVSH are named inventors on patent 
applications for vectored vaccines and immunization regimens. 
Male Female Total (% 
of all 
screened)
All volunteers screened 504 483 987 (99.7)
New diagnoses 14 9 23 (2.4)
Median age at new diagnosis (IQR)* 32.2 
(22.1–32.2)
25.4 
(20.7–34.4)
30.0 
(21.2–37.5)
Age group†
 18–29 5/341 6/338 –
 30–40 6/111 2/100 –
 41–65 3/52 1/45 –
Alcohol excess with abnormal LFTs 2 0 2 (0.2)
Nephrotic syndrome 1 0 1 (0.1)
Hypercholesterolemia 2 0 2 (0.2)
Hemoglobinopathy 0 4 4 (0.4)
Iron defi ciency anemia‡ 0 2 2 (0.2)
Chronic hepatitis B 1 0 1 (0.1)
Chronic hepatitis C 2 0 2 (0.2)
Hypertension 4 1 5 (0.5)
Cardiac murmur requiring investigation 1 1 2 (0.2)
Supraclavicular mass 0 1 1 (0.1)
Allergic skin rash with eosinophilia 1 0 1 (0.1)
Tungiasis 1 0 1 (0.1)
More than one abnormality may coexist in a single participant. LFTs = liver function tests.
*IQR = interquartile range, Mann-Whitney p = 0.27.
†Chi-square for trend with age p = 0.02 males, p = 0.82 females.
‡Considered clinically signifi cant in males or postmenopausal females, or in any volunteer if Hb < 10 g/dL.
 Table 1.  Frequency of new medical problems in healthy male and female volunteers. 
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